onasemnogene abeparvovec

AXP000250.1 · Viral vector gene therapy

Platform
AAV9 vector
Targets
SMN1
Originator
Nationwide Children's Hospital / AveXis
Sponsor
Novartis Gene Therapies

Names

NameTypeSource
onasemnogene abeparvovecpreferred namecurator
Itvismabrandfda
Zolgensmabrandfda
OAV-101codecurator
AVXS-101former codecurator

Virus

Role
In vivo gene transfer
Family
Parvoviridae
Virus
adeno-associated virus 9
Strain
AAV9
Replication
non replicating
Modifications
self-complementary genome, cytomegalovirus enhancer/chicken beta-actin hybrid promoter
Transgenes
SMN1
Route
intravenous, intrathecal
Source
evidence

Approvals

AgencyRegionDateStatusBrandIndicationSource
FDAUS2019-05-24approvedZolgensmaPaediatric patients under 2 years with spinal muscular atrophy and bi-allelic SMN1 mutations (intravenous)source
PMDAJP2020-03-19approvedZolgensmaSpinal muscular atrophy, including genetically diagnosed pre-symptomatic SMA, in patients who have tested negative for anti-AAV9 antibodiessource
EMAEU2020-05-18approvedZolgensma5q SMA with a bi-allelic SMN1 mutation and either a clinical diagnosis of type 1 or up to 3 SMN2 copies; conditional at first, full from 2022-05-17source
FDAUS2025-11-24approvedItvismaSpinal muscular atrophy in patients 2 years and older with a confirmed SMN1 mutation (intrathecal)source
PMDAJP2026-04-03approvedZolgensmaSpinal muscular atrophy; the intrathecal formulation, approved as a separate product (Zolgensma Suspension for Intrathecal Injection). PMDA has not yet published a review report for this approval, so only the product and the date are recorded heresource

Clinical trials (22)

TrialTitleStatusPhaseStartPrimary completionEnrolmentConditions
NCT07737756A Real-World Medical Chart Review of Spinal Muscular Atrophy Patients Treated With Onasemnogene Abeparvovec in Saudi ArabiaNot yet recruiting2026-11-302027-02-286Spinal Muscular Atrophy
NCT07444450A Study to Learn About the Safety and Effects of Salanersen (BIIB115) When Given to Babies With Spinal Muscular Atrophy (SMA) Who Were Previously Treated With Onasemnogene AbeparvovecRecruitingPhase 32026-10-312029-07-2742Muscular Atrophy, Spinal
NCT07767890A Study of the Safety and Effectiveness of Onasemnogene Abeparvovec (Zolgensma) Intrathecal Injection in Spinal Muscular Atrophy PatientsRecruiting2026-10-072031-03-3180Spinal Muscular Atrophy
NCT07448610ASsessing The REAl-world Safety & Effectiveness of Spinal Muscular Atrophy Participants Treated With Intrathecal Onasemnogene Abeparvovec-brve (OAV101B) (ITVISMA®): A U.S. Pragmatic Multicenter Study (STREAM)RecruitingPhase 42026-08-272032-05-0336Spinal Muscular Atrophy
NCT06019637A Long-term Safety Study in Brazilian Patients With a Diagnosis of Spinal Muscular Atrophy Treated With ZolgensmaRecruiting2023-11-272042-01-0250Spinal Muscular Atrophies
NCT05386680Phase IIIb, Open-label, Multi-center Study to Evaluate Safety, Tolerability and Efficacy of OAV101 Administered Intrathecally to Participants With SMA Who Discontinued Treatment With Nusinersen or RisdiplamCompletedPhase 32023-01-122024-11-2927Spinal Muscular Atrophy
NCT05335876Long-term Follow-up of Patients With Spinal Muscular Atrophy Treated With OAV101 in Clinical TrialsActive not recruitingPhase 32022-12-192031-04-2920Spinal Muscular Atrophy (SMA)
NCT05575011A Study to Learn About the Safety of BIIB115 Injections and How BIIB115 is Processed in the Bodies of Healthy Adult Male Volunteers and of Pediatric Participants With Spinal Muscular Atrophy Who Previously Took Onasemnogene AbeparvovecActive not recruitingPhase 12022-10-102031-11-1462Healthy Volunteer; Muscular Atrophy, Spinal
NCT05089656Efficacy and Safety of Intrathecal OAV101 (AVXS-101) in Pediatric Patients With Type 2 Spinal Muscular Atrophy (SMA)CompletedPhase 32022-02-012024-11-12126Type 2 Spinal Muscular Atrophy
NCT05073133Safety and Efficacy of Intravenous OAV101 (AVXS-101) in Pediatric Patients With Spinal Muscular Atrophy (SMA) (OFELIA)CompletedPhase 42021-11-042023-08-0816Muscular Atrophy, Spinal
NCT04851873Safety and Efficacy of Intravenous OAV101 (AVXS-101) in Pediatric Patients With Spinal Muscular Atrophy (SMA)CompletedPhase 32021-09-082023-06-1324Spinal Muscular Atrophy
NCT04488133A Study to Learn About the Effect of Nusinersen (BIIB058) Given as Injections to Children With Spinal Muscular Atrophy (SMA) Who Were Previously Treated With Onasemnogene Abeparvovec (RESPOND)CompletedPhase 42021-01-042025-10-0946Muscular Atrophy, Spinal
NCT04042025Long-term Follow-up Study of Patients Receiving Onasemnogene Abeparvovec-xioiActive not recruitingPhase 32020-02-102035-12-3185SMA; Spinal Muscular Atrophy Type I; Spinal Muscular Atrophy Type II; Spinal Muscular Atrophy Type III
NCT03837184Single-Dose Gene Replacement Therapy Using for Patients With Spinal Muscular Atrophy Type 1 With One or Two SMN2 CopiesCompletedPhase 32019-05-312021-06-292Spinal Muscular Atrophy Type I
NCT04174157Registry of Patients With a Diagnosis of Spinal Muscular Atrophy (SMA)Recruiting2018-09-252038-06-30700Spinal Muscular Atrophy (SMA)
NCT03461289Single-Dose Gene Replacement Therapy Clinical Trial for Participants With Spinal Muscular Atrophy Type 1CompletedPhase 32018-08-162020-09-1133SMA
NCT03505099Pre-Symptomatic Study of Intravenous Onasemnogene Abeparvovec-xioi in Spinal Muscular Atrophy (SMA) for Patients With Multiple Copies of SMN2CompletedPhase 32018-04-022021-06-1530Spinal Muscular Atrophy
NCT03381729Study of Intrathecal Administration of Onasemnogene Abeparvovec-xioi for Spinal Muscular AtrophyTerminatedPhase 12017-12-142021-11-1832Spinal Muscular Atrophy
NCT03306277Gene Replacement Therapy Clinical Trial for Participants With Spinal Muscular Atrophy Type 1CompletedPhase 32017-10-242019-11-1222Gene Therapy; SMA - Spinal Muscular Atrophy
NCT03421977Long-Term Follow-up Study for Patients From AVXS-101-CL-101Active not recruiting2017-09-212030-12-0213Spinal Muscular Atrophy 1
NCT02122952Gene Transfer Clinical Trial for Spinal Muscular Atrophy Type 1CompletedPhase 12014-05-052017-12-1515Spinal Muscular Atrophy 1
NCT03955679AveXis Managed Access Program Cohort for Access to AVXS-101Approved for marketingSpinal Muscular Atrophy

Recent changes

No changes recorded in its trials yet.

Clinical papers

PubMedTitleJournalYearLinked by
PMID 41217888Trach and treat: Safety and motor outcomes following onasemnogene abeparvovec in patients with spinal muscular atrophy and tracheostomies in the RESTORE registry.Journal of neuromuscular diseases2026cited by trial NCT04174157
PMID 41360993Intrathecal onasemnogene abeparvovec in treatment-naive patients with spinal muscular atrophy: a phase 3, randomized controlled trial.Nature medicine2026cited by trial NCT05089656
PMID 41360995Intrathecal onasemnogene abeparvovec for treatment-experienced patients with spinal muscular atrophy: a phase 3b, open-label trial.Nature medicine2026cited by trial NCT05386680
PMID 41431300Treatment evolution in spinal muscular atrophy: insights from the SMArtCARE registry.Brain : a journal of neurology2026name in abstract: onasemnogene abeparvovec
PMID 41545588Contaminating plasmid sequences and disrupted vector genomes in the liver following adeno-associated virus gene therapy.Nature medicine2026name in abstract: onasemnogene abeparvovec
PMID 41718941Summary of Research: Risdiplam Treatment Following Onasemnogene Abeparvovec in Individuals with Spinal Muscular Atrophy: A Multicenter Case Series.Advances in therapy2026name in title: onasemnogene abeparvovec
PMID 41757676Comparison of Nusinersen Monotherapy Versus Combination Therapy With Nusinersen and Onasemnogene Abeparvovec in Spinal Muscular Atrophy Type 1 Patients With Two SMN2 Copies: A Multicenter Study From Türkiye.Muscle & nerve2026name in title: onasemnogene abeparvovec
PMID 41795276Outcomes of combination therapy with nusinersen, onasemnogene abeparvovec, and risdiplam over 3.5 years in a patient with prenatally diagnosed spinal muscular atrophy type 0: A case report.Brain & development2026name in title: onasemnogene abeparvovec
PMID 41854353Onasemnogene Abeparvovec in Type I Spinal Muscular Atrophy: 24-Month Follow-Up From the Italian Registry.Annals of clinical and translational neurology2026name in title: onasemnogene abeparvovec
PMID 41964328Risdiplam Add-On Therapy Following Onasemnogene Abeparvovec in Children With Spinal Muscular Atrophy and 2 SMN2 Copies: A Multi-Center Case Series.Muscle & nerve2026name in title: onasemnogene abeparvovec
PMID 42016922Safety and efficacy of intravenous onasemnogene abeparvovec gene therapy in patients with spinal muscular atrophy type 1: interim analysis from LT-001, a long-term follow-up study of patients from the START study.EClinicalMedicine2026cited by trial NCT02122952
PMID 42265796Onasemnogene Abeparvovec in Patients With SMA: Interim Results of the RESTORE Registry in Japan.Annals of clinical and translational neurology2026cited by trial NCT04174157
PMID 42400303Adeno-Associated Virus Gene Therapy for Spinal Muscular Atrophy Induces Hepatotoxicity via Cytokine and Macrophage Activation.Liver international : official journal of the International Association for the Study of the Liver2026name in abstract: onasemnogene abeparvovec
PMID 42563034Longitudinal Dosing Patterns and Treatment Costs Among Patients with Spinal Muscular Atrophy Initiating Nusinersen and Risdiplam.Advances in therapy2026name in abstract: onasemnogene abeparvovec
PMID 42601027Gene therapy benefits in a small cohort of symptomatic 5q spinal muscular atrophy patients and real world pediatric outcomes.Jornal de pediatria2026name in abstract: onasemnogene abeparvovec
PMID 42612481Genetic susceptibility to thrombotic microangiopathy in a 10-month-old patient with SMA type 1: a caveat for gene therapy eligibility.Neuromuscular disorders : NMD2026name in abstract: onasemnogene abeparvovec
PMID 39689850Onasemnogene Abeparvovec is Safe in Hemolytic Disease of the Newborn: A Case Report.Neuropediatrics2025name in title: onasemnogene abeparvovec
PMID 39804575Safety and Efficacy of IV Onasemnogene Abeparvovec for Pediatric Patients With Spinal Muscular Atrophy: The Phase 3b SMART Study.Neurology2025cited by trial NCT04851873
PMID 39955617Pilocytic astrocytoma in a child with spinal muscular atrophy treated with onasemnogene abeparvovec.Molecular therapy : the journal of the American Society of Gene Therapy2025name in title: onasemnogene abeparvovec
PMID 40013321Characteristics of Patients With Spinal Muscular Atrophy Who Have Switched Treatments: A Multi-Center Experience in the United Kingdom.Muscle & nerve2025name in abstract: onasemnogene abeparvovec
PMID 40025752Early Treatment in Preterm Twins With Spinal Muscular Atrophy.Journal of child neurology2025name in abstract: onasemnogene abeparvovec
PMID 40269260Fatal outcomes following onasemnogene abeparvovec in advanced-stage spinal muscular atrophy.Gene therapy2025name in title: onasemnogene abeparvovec
PMID 40365794Evaluation of cardiac function in patients with SMA after treatment with onasemnogene abeparvovec.Pediatrics international : official journal of the Japan Pediatric Society2025name in title: onasemnogene abeparvovec
PMID 40533496Thrombotic microangiopathy following gene therapy for 5q-spinal muscular atrophy.Gene therapy2025name in abstract: onasemnogene abeparvovec
PMID 40538493Eculizumab for Thrombotic Microangiopathy Induced by Onasemnogene Abeparvovec in Spinal Muscular Atrophy.Case reports in nephrology and dialysis2025name in title: onasemnogene abeparvovec
PMID 40624473Risdiplam treatment following onasemnogene abeparvovec in individuals with spinal muscular atrophy: a multicenter case series.BMC neurology2025name in title: onasemnogene abeparvovec
PMID 40625130REGISTRE SMA FRANCE: A nationwide observational registry of patients with spinal muscular atrophy in France.Journal of neuromuscular diseases2025name in abstract: onasemnogene abeparvovec
PMID 40630496Real-world outcomes of spinal muscular atrophy treatment with onasemnogene abeparvovec in Croatia: a comprehensive case series and literature review.Frontiers in medicine2025name in title: onasemnogene abeparvovec
PMID 40705999Reduction of Preexisting AAV9 Antibody Titers Before Onasemnogene Abeparvovec Administration in Twins With Spinal Muscular Atrophy.Neurology2025name in title: onasemnogene abeparvovec
PMID 40863714Eosinophilic Esophagitis in a 3-Year-Old Girl with Spinal Muscular Atrophy Type 1: The First Reported Case.Pediatric reports2025name in abstract: onasemnogene abeparvovec
PMID 40956616Open-label phase IV trial evaluating nusinersen after onasemnogene abeparvovec in children with spinal muscular atrophy.The Journal of clinical investigation2025cited by trial NCT04488133
PMID 40965051Treatment Outcome of Risdiplam and Onasemnogene Abeparvovec in an Infant With Spinal Muscular Atrophy Dependent on Prolonged Invasive Ventilation.Journal of paediatrics and child health2025name in title: onasemnogene abeparvovec
PMID 41122612Administration of Onasemnogene Abeparvovec in an Infant With Spinal Muscular Atrophy and PCR-Confirmed SARS-CoV-2 Infection.Cureus2025name in title: onasemnogene abeparvovec
PMID 37657961Later efficacy of nusinersen treatment in adult patients with spinal muscular atrophy: A retrospective case study with a median 4-year follow-up.Brain & development2024name in abstract: onasemnogene abeparvovec
PMID 38233181Onasemnogene Abeparvovec Treatment after Nusinersen in an Infant with Spinal Muscular Atrophy Type 1.The Kurume medical journal2024name in title: onasemnogene abeparvovec
PMID 38250783Real-World Outcomes in Patients with Spinal Muscular Atrophy Treated with Onasemnogene Abeparvovec Monotherapy: Findings from the RESTORE Registry.Journal of neuromuscular diseases2024name in title: onasemnogene abeparvovec
PMID 38306058Repeated AAV9 Titer Determination in a Presymptomatic SMA Patient with Three SMN2 Gene Copies - A Case Report.Journal of neuromuscular diseases2024name in abstract: onasemnogene abeparvovec
PMID 38676690[Experience of the treatment of spinal muscular atrophy type 3 Kugelberg-Welander with Nusinersen].Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova2024name in abstract: onasemnogene abeparvovec
PMID 38733387JEWELFISH: 24-month results from an open-label study in non-treatment-naïve patients with SMA receiving treatment with risdiplam.Journal of neurology2024name in abstract: onasemnogene abeparvovec
PMID 38790585Onasemnogene Abeparvovec Administration via Peripherally Inserted Central Catheter: A Case Report.Children (Basel, Switzerland)2024name in title: onasemnogene abeparvovec
PMID 38839888Gene replacement therapy for spinal muscular atrophy: safety and preliminary efficacy in a Brazilian cohort.Gene therapy2024name in abstract: onasemnogene abeparvovec
PMID 39111255Risk-benefit profile of onasemnogene abeparvovec in older and heavier children with spinal muscular atrophy type 1.Neuromuscular disorders : NMD2024name in title: onasemnogene abeparvovec
PMID 39327607Postnatal management of preterm infants with spinal muscular atrophy: experience from German newborn screening.Orphanet journal of rare diseases2024name in abstract: onasemnogene abeparvovec
PMID 39342433Onasemnogene-abeparvovec administration to premature infants with spinal muscular atrophy.Annals of clinical and translational neurology2024name in title: onasemnogene abeparvovec
PMID 39370660Outcomes of early-treated infants with spinal muscular atrophy: A multicenter, retrospective cohort study.Muscle & nerve2024name in abstract: onasemnogene abeparvovec
PMID 39625559Respiratory outcomes of onasemnogene abeparvovec treatment for spinal muscular atrophy: national real-world cohort study.European journal of pediatrics2024name in title: onasemnogene abeparvovec
PMID 35474244Adeno-associated virus serotype 9 antibody titers in patients with SMA pre-screened for treatment with onasemnogene abeparvovec -routine care evidence.Gene therapy2023name in title: onasemnogene abeparvovec
PMID 35606491Onasemnogene abeparvovec gene replacement therapy for the treatment of spinal muscular atrophy: a real-world observational study.Gene therapy2023name in title: onasemnogene abeparvovec
PMID 36855136Treatment of spinal muscular atrophy with Onasemnogene Abeparvovec in Switzerland: a prospective observational case series study.BMC neurology2023name in title: onasemnogene abeparvovec
PMID 37091744Gene therapy for spinal muscular atrophy is considerably effective when administered as early as possible after birth.Molecular genetics and metabolism reports2023name in abstract: onasemnogene abeparvovec
PMID 37149951Real-Life Outcome After Gene Replacement Therapy for Spinal Muscular Atrophy: A Multicenter Experience.Pediatric neurology2023name in abstract: onasemnogene abeparvovec
PMID 37598295Epithelioid neoplasm of the spinal cord in a child with spinal muscular atrophy treated with onasemnogene abeparvovec.Molecular therapy : the journal of the American Society of Gene Therapy2023name in title: onasemnogene abeparvovec
PMID 37780708Case report: A case of spinal muscular atrophy in a preterm infant: risks and benefits of treatment.Frontiers in neurology2023name in abstract: onasemnogene abeparvovec
PMID 37841286A homozygous missense variant in the YG box domain in an individual with severe spinal muscular atrophy: a case report and variant characterization.Frontiers in cellular neuroscience2023name in abstract: onasemnogene abeparvovec
PMID 37907848Changes in electrophysiological findings of spinal muscular atrophy type I after the administration of nusinersen and onasemnogene abeparvovec: two case reports.BMC neurology2023name in title: onasemnogene abeparvovec
PMID 38090542Sequential treatment with nusinersen, Zolgensma® and risdiplam in a paediatric patient with spinal muscular atrophytype 1: a case report.Acta myologica : myopathies and cardiomyopathies : official journal of the Mediterranean Society of Myology2023name in title: Zolgensma
PMID 34388834[Thrombotic Microangiopathy (TMA) after Gene Replacemant Therapy (GRT) due to Spinal Muscular Atrophy: Case Summary and Recommendations for Treatment].Klinische Padiatrie2022name in abstract: onasemnogene abeparvovec
PMID 34756190Gene replacement therapy with onasemnogene abeparvovec in children with spinal muscular atrophy aged 24 months or younger and bodyweight up to 15 kg: an observational cohort study.The Lancet. Child & adolescent health2022name in title: onasemnogene abeparvovec
PMID 35351784Child Neurology: Pathologically Confirmed Thrombotic Microangiopathy Caused by Onasemnogene Abeparvovec Treatment for SMA.Neurology2022name in title: onasemnogene abeparvovec
PMID 35584395Fatal thrombotic microangiopathy case following adeno-associated viral SMN gene therapy.Blood advances2022name in abstract: onasemnogene abeparvovec
PMID 35715566Onasemnogene abeparvovec for presymptomatic infants with two copies of SMN2 at risk for spinal muscular atrophy type 1: the Phase III SPR1NT trial.Nature medicine2022cited by trial NCT03505099
PMID 35715567Onasemnogene abeparvovec for presymptomatic infants with three copies of SMN2 at risk for spinal muscular atrophy: the Phase III SPR1NT trial.Nature medicine2022cited by trial NCT03505099
PMID 35924856Hemophagocytic lymphohistiocytosis following gene replacement therapy in a child with type 1 spinal muscular atrophy.Journal of clinical pharmacy and therapeutics2022name in abstract: onasemnogene abeparvovec
PMID 36125439Novartis Confirms Deaths of Two Patients Treated with Gene Therapy Zolgensma.Human gene therapy2022name in title: Zolgensma
PMID 36349185Switching therapies: safety profile of Onasemnogene abeparvovec-xioi in a SMA1 patient previously treated with Risdiplam.Acta myologica : myopathies and cardiomyopathies : official journal of the Mediterranean Society of Myology2022name in title: onasemnogene abeparvovec
PMID 33259859Thrombotic Microangiopathy Following Onasemnogene Abeparvovec for Spinal Muscular Atrophy: A Case Series.The Journal of pediatrics2021name in title: onasemnogene abeparvovec
PMID 33743238Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy in patients with two copies of SMN2 (STR1VE): an open-label, single-arm, multicentre, phase 3 trial.The Lancet. Neurology2021cited by trial NCT03306277
PMID 33959970Time is muscle: A recommendation for early treatment for preterm infants with spinal muscular atrophy.Muscle & nerve2021name in abstract: onasemnogene abeparvovec
PMID 33999158Five-Year Extension Results of the Phase 1 START Trial of Onasemnogene Abeparvovec in Spinal Muscular Atrophy.JAMA neurology2021cited by trial NCT03421977
PMID 34383289Clinical Trial and Postmarketing Safety of Onasemnogene Abeparvovec Therapy.Drug safety2021cited by trial NCT02122952
PMID 34536405Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy type 1 (STR1VE-EU): an open-label, single-arm, multicentre, phase 3 trial.The Lancet. Neurology2021cited by trial NCT03461289
PMID 34608334Biodistribution of onasemnogene abeparvovec DNA, mRNA and SMN protein in human tissue.Nature medicine2021name in title: onasemnogene abeparvovec
PMID 32515646Clinical Course in a Patient With Spinal Muscular Atrophy Type 0 Treated With Nusinersen and Onasemnogene Abeparvovec.Journal of child neurology2020name in title: onasemnogene abeparvovec
PMID 33003005Spinal Muscular Atrophy.Continuum (Minneapolis, Minn.)2020name in abstract: onasemnogene abeparvovec
PMID 30548438Health outcomes in spinal muscular atrophy type 1 following AVXS-101 gene replacement therapy.Pediatric pulmonology2019cited by trial NCT02122952
PMID 30879249Survival, Motor Function, and Motor Milestones: Comparison of AVXS-101 Relative to Nusinersen for the Treatment of Infants with Spinal Muscular Atrophy Type 1.Advances in therapy2019cited by trial NCT02122952
PMID 31277975Impact of Age and Motor Function in a Phase 1/2A Study of Infants With SMA Type 1 Receiving Single-Dose Gene Replacement Therapy.Pediatric neurology2019cited by trial NCT02122952
PMID 31488615Combination therapy with nusinersen and AVXS-101 in SMA type 1.Neurology2019name in title: AVXS-101
PMID 29091557Single-Dose Gene-Replacement Therapy for Spinal Muscular Atrophy.The New England journal of medicine2017cited by trial NCT02122952

Other papers

Preclinical studies, reviews and other papers that name it, newest 100 shown.

PubMedTitleJournalYearLinked by
PMID 39794476Identifying novel response markers for spinal muscular atrophy revealed by targeted proteomics following gene therapy.Gene therapy2026name in abstract: Zolgensma
PMID 40148593Organoids - the future of pre-clinical development of AAV gene therapy for CNS disorders.Gene therapy2026name in abstract: Zolgensma
PMID 40169808Early life safety profiling of gene therapy for spinal muscular atrophy.Gene therapy2026name in abstract: onasemnogene abeparvovec
PMID 40569556Cost-effectiveness of treatments for presymptomatic newborn patients with spinal muscular atrophy and two or three copies of the survival motor neuron 2 gene in Italy.The European journal of health economics : HEPAC : health economics in prevention and care2026name in abstract: onasemnogene abeparvovec
PMID 41109767Updates of spinal muscular atrophy in advanced therapies.Journal of the Formosan Medical Association = Taiwan yi zhi2026name in abstract: onasemnogene abeparvovec
PMID 41212681Onasemnogene abeparvovec gene therapy for treatment of patients with spinal muscular atrophy: Updated real-world practical considerations.Journal of neuromuscular diseases2026name in title: onasemnogene abeparvovec
PMID 41284552Delphi consensus on gene therapy of spinal muscular atrophy with onasemnogene abeparvovec in Germany, Austria and Switzerland-part I-systematic literature review and existing evidence.Journal of neuromuscular diseases2026name in title: onasemnogene abeparvovec
PMID 41343897Promises past and future - Gene therapy and the actualisation of future expectations.Social science & medicine (1982)2026name in abstract: Zolgensma
PMID 41398093Clinical relevance of zebrafish for gene variants testing. Proof-of-principle with SMN1/SMA.EMBO molecular medicine2026name in abstract: onasemnogene abeparvovec
PMID 41496894CRISPR-Cas editing technologies for viral-mediated gene therapies of human diseases: Mechanisms, progress, and challenges.Molecular therapy. Nucleic acids2026name in abstract: Zolgensma
PMID 41508057Swallowing and feeding after disease-modifying treatment for spinal muscular atrophy: a systematic review of assessment modalities and outcomes.Orphanet journal of rare diseases2026name in abstract: onasemnogene abeparvovec
PMID 41566962Fusionless spinal surgery in children with spinal muscular atrophy type 1 with bipolar system: a preliminary communication.Journal of pediatric orthopedics. Part B2026name in abstract: onasemnogene abeparvovec
PMID 41574584The High Cost of Gene Therapy: Managing Onasemnogene Abeparvovec's Economic Impact.The Annals of pharmacotherapy2026name in title: onasemnogene abeparvovec
PMID 41606122Author Correction: Intrathecal onasemnogene abeparvovec for treatment-experienced patients with spinal muscular atrophy: a phase 3b, open-label trial.Nature medicine2026name in title: onasemnogene abeparvovec
PMID 41671781Longitudinal assessment of respiratory status utilising the amended Great Ormond Street Respiratory Score in treated spinal muscular atrophy type 1 children.Neuromuscular disorders : NMD2026name in abstract: onasemnogene abeparvovec
PMID 41680498Patient reported outcome measures in spinal muscular atrophy and duchenne muscular dystrophy: review of instruments and their inclusion in clinical and regulatory processes.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology2026name in abstract: onasemnogene abeparvovec
PMID 41699720Swallowing development in infants and toddlers with spinal muscular atrophy following therapy compared to healthy controls: the prospective controlled DySMA trial.Orphanet journal of rare diseases2026name in abstract: onasemnogene abeparvovec
PMID 41720432Skeletal muscle in spinal muscular atrophy: Critical insights from pathogenesis to therapeutic strategies.Neurobiology of disease2026name in abstract: onasemnogene abeparvovec
PMID 41782369Low-dose AAV9-SMN1 with CNS-selective expression delivers efficacy and favorable safety in spinal muscular atrophy.Molecular therapy : the journal of the American Society of Gene Therapy2026name in abstract: onasemnogene abeparvovec
PMID 41813830Securitization as a means to pay for cell and gene therapies for orphan diseases: a simulation study.Gene therapy2026name in abstract: Zolgensma
PMID 41817636RNA biomarkers in spinal muscular atrophy: enhancing pathogenesis understanding and guiding precision medicine.Cellular and molecular life sciences : CMLS2026name in abstract: onasemnogene abeparvovec
PMID 41933930Adeno-Associated Virus Gene Delivery to Hard-to-Transduce Tissues: Biological Barriers, Engineering Strategies, and Clinical Challenges.Human gene therapy2026name in abstract: Zolgensma
PMID 41944036Incidence, Timing and Clinical Significance of Immune-Mediated Myocardial Injury and Myocarditis After Gene Replacement Therapy: A Systematic Review and Meta-Analysis.Circulation. Heart failure2026name in abstract: onasemnogene abeparvovec
PMID 42023171Hip displacement management in spinal muscular atrophy in the era of disease modifying therapies: a Delphi consensus study in the UK.EClinicalMedicine2026name in abstract: onasemnogene abeparvovec
PMID 42084965Onasemnogene Abeparvovec in Early-Onset Spinal Muscular Atrophy: An Indian Experience.Annals of Indian Academy of Neurology2026name in title: onasemnogene abeparvovec
PMID 42095821[Spinal muscular atrophy: Clinical and genetic aspects, and therapeutic alternatives].Revista medica del Instituto Mexicano del Seguro Social2026name in abstract: onasemnogene abeparvovec
PMID 42097918Management of spinal muscular atrophy: nursing clinical commentary and best practices update.Journal of pediatric nursing2026name in abstract: onasemnogene abeparvovec
PMID 42104248Exploring the phenotypic and genotypic spectrum of spinal muscular atrophy in Bangladeshi children.BMC neurology2026name in abstract: onasemnogene abeparvovec
PMID 42105903Beyond SMN1 mutation: environmental predispositions and epigenetic contributors to phenotypic variability and disease severity in spinal muscular atrophy.Neuroscience2026name in abstract: onasemnogene abeparvovec
PMID 42137283Elective preterm birth for earlier spinal muscular atrophy treatment.Molecular therapy. Advances2026name in abstract: onasemnogene abeparvovec
PMID 42157963Global age-related seroprevalence for adeno-associated virus serotype 9 immunoglobulin G.Molecular therapy. Advances2026name in abstract: onasemnogene abeparvovec
PMID 42161221Characterization of Safety Signals for Spinal Muscular Atrophy Treatments in Children Aged 0 to 3 Years Potential Safety Patterns for Further Investigation.Pediatric neurology2026name in abstract: onasemnogene abeparvovec
PMID 42177183Long-term comparative analysis of AAV9-mediated gene replacement therapies for spinal muscular atrophy in mice.Nature communications2026name in abstract: Zolgensma
PMID 42203536Advancements in Prenatal Diagnosis and Potential Fetal Therapies for Spinal Muscular Atrophy.Clinical therapeutics2026name in abstract: onasemnogene abeparvovec
PMID 42211742External controls for rare disease drug development: Lessons for emerging and advanced therapeutic modalities.Molecular therapy. Advances2026name in abstract: onasemnogene abeparvovec
PMID 42233939Cost-Effectiveness of Universal Newborn Screening and Disease-Modifying Therapies for Spinal Muscular Atrophy in Taiwan.Value in health regional issues2026name in abstract: onasemnogene abeparvovec
PMID 42240059Determinants of hepatic enzyme elevations following onasemnogene abeparvovec: Results from a unified immunomodulation protocol.Journal of neuromuscular diseases2026name in title: onasemnogene abeparvovec
PMID 42260056Modeling the Budget Impact of Disease-Modifying Therapies in Infantile-Onset Spinal Muscular Atrophy.Clinical drug investigation2026name in abstract: onasemnogene abeparvovec
PMID 42309883Gene therapy in pediatric patients with spinal muscular atrophy in Kazakhstan: Challenges and achievements.Pediatrics and neonatology2026name in abstract: onasemnogene abeparvovec
PMID 42432779Vulnerability, protection and fairness: ethical and regulatory limits in small-N gene therapy trials.Trials2026name in abstract: Zolgensma
PMID 42449943Trends in the Engineering of Adeno-Associated Virus (AAV) for Precision Gene Delivery to the Central Nervous System (CNS).International journal of molecular sciences2026name in abstract: Zolgensma
PMID 42582471Therapeutic strategies for spinal muscular atrophy: the history and future perspective.Frontiers in human neuroscience2026name in abstract: onasemnogene abeparvovec
PMID 42658895Delphi consensus on gene therapy of spinal muscular atrophy with onasemnogene abeparvovec in Germany, Austria and Switzerland - part II - expert based recommendations for surveillance and management of side-effects.Journal of neuromuscular diseases2026name in title: onasemnogene abeparvovec
PMID 42668237289th ENMC international workshop: assessing and managing emerging AAV related toxicities after gene therapy for neuromuscular disorders, 26 - 28 September 2025, Hoofddorp, The Netherlands.Neuromuscular disorders : NMD2026name in abstract: onasemnogene abeparvovec
PMID 42713019Spinal muscular atrophy in the disease-modifying therapy era: successes, limitations and future directions.Frontiers in molecular medicine2026name in abstract: onasemnogene abeparvovec
PMID 42749594Consensus on gene therapy for spinal muscular atrophy in Taiwan.Journal of the Formosan Medical Association = Taiwan yi zhi2026name in abstract: onasemnogene abeparvovec
PMID 42776081Spinal muscular atrophy as a blueprint for precision therapy in neuromuscular disease.Expert reviews in molecular medicine2026name in abstract: onasemnogene abeparvovec
PMID 42779866P5 promoter-mediated incorporation explains REP/CAP manufacturing contaminants in patient liver after rAAV gene therapy.medRxiv : the preprint server for health sciences2026name in abstract: Zolgensma
PMID 42799810Real-World Treatment Patterns in Patients with Spinal Muscular Atrophy Receiving Multiple Disease-Modifying Therapies.Advances in therapy2026name in abstract: onasemnogene abeparvovec
PMID 42807701Therapeutic advances in spinal muscular atrophy: a review of clinical, safety, and economic considerations.Frontiers in pharmacology2026name in abstract: onasemnogene abeparvovec
PMID 42869088Consensus on the Use of Intrathecal Gene Therapy for Spinal Muscular Atrophy.Neuropediatrics2026name in abstract: onasemnogene abeparvovec
PMID 42894980Making trade-offs explicit: development and pilot of a Belgian MCDA framework for orphan drug appraisal.International journal of technology assessment in health care2026name in abstract: onasemnogene abeparvovec
PMID 42903708The role of vascular pathology in SMA: implications for pathogenesis and treatment.Frontiers in cellular neuroscience2026name in abstract: onasemnogene abeparvovec
PMID 42983461Use of European registries to characterise the changing landscape of disease progression and treatment of spinal muscular atrophy (SMA): opportunities, pitfalls and challenges.Orphanet journal of rare diseases2026name in abstract: onasemnogene abeparvovec
PMID 43016315Indirect treatment comparisons of nusinersen versus onasemnogene abeparvovec-brve in treatment-naïve and -experienced spinal muscular atrophy patients.Journal of medical economics2026name in title: onasemnogene abeparvovec
PMID 39039945Genetic counselors' awareness and attitudes regarding gene therapies.Journal of genetic counseling2025name in abstract: onasemnogene abeparvovec
PMID 39333302Onasemnogene Abeparvovec Gene Therapy and Risdiplam for the Treatment of Spinal Muscular Atrophy in Thailand: A Cost-Utility Analysis.Applied health economics and health policy2025name in title: onasemnogene abeparvovec
PMID 39368017Managed Entry Agreements for High-Cost, One-Off Potentially Curative Therapies: A Framework and Calculation Tool to Determine Their Suitability.PharmacoEconomics2025name in abstract: onasemnogene abeparvovec
PMID 39426797Clinicogenetic characterization and response to disease-modifying therapies in spinal muscular atrophy: real-world experience from a reference center in Southern Brazil.Jornal de pediatria2025name in abstract: onasemnogene abeparvovec
PMID 39604484Gene-based therapy for the treatment of spinal muscular atrophy types 1 and 2 : a systematic review and meta-analysis.Gene therapy2025name in abstract: onasemnogene abeparvovec
PMID 39708835Advances in Disease-Modifying Therapeutics for Chronic Neuromuscular Disorders.Seminars in respiratory and critical care medicine2025name in abstract: onasemnogene abeparvovec
PMID 39739027Scoliosis development in 5q-spinal muscular atrophy under disease modifying therapies.European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society2025name in abstract: onasemnogene abeparvovec
PMID 39913410Drug-induced autoimmune-like hepatitis: A disproportionality analysis based on the FAERS database.PloS one2025name in abstract: onasemnogene abeparvovec
PMID 39969920The Effect of Disease-Modifying Therapies on Lung Function and Respiratory Muscle Strength in Spinal Muscular Atrophy: Systematic Review and Meta-Analysis.Respiratory care2025name in abstract: onasemnogene abeparvovec
PMID 39982664Cost comparison analysis of onasemnogene abeparvovec and nusinersen for treatment of patients with spinal muscular atrophy type 1 in the Netherlands.The European journal of health economics : HEPAC : health economics in prevention and care2025name in title: onasemnogene abeparvovec
PMID 39993407The Legal Issues Regarding the Reimbursement of Drugs Used to Treat Muscular Atrophy and the Actual Situation in the Slovak Republic.European journal of health law2025name in abstract: Zolgensma
PMID 40009418Safety of Onasemnogene Abeparvovec Administration to Type 1 SMA Patients Who Have Received Risdiplam.Journal of clinical neuromuscular disease2025name in title: onasemnogene abeparvovec
PMID 40022865Mortality of symptomatic children with spinal muscular atrophy in the era of disease-modifying therapies.Neuromuscular disorders : NMD2025name in abstract: onasemnogene abeparvovec
PMID 40104176Real-world evidence in spinal muscular atrophy: addressing heterogeneity of populations and treatment comparisons.The Lancet regional health. Europe2025name in abstract: onasemnogene abeparvovec
PMID 40253479Structural characterization of antibody-responses following Zolgensma treatment for AAV capsid engineering to expand patient cohorts.Nature communications2025name in title: Zolgensma
PMID 40289052Cost-Effectiveness of Newborn Screening for Spinal Muscular Atrophy in Australian Hospitals.Neurology and therapy2025name in abstract: onasemnogene abeparvovec
PMID 40329332Postmarketing adverse events associated with onasemnogene abeparvovec: a real-world pharmacovigilance study.Orphanet journal of rare diseases2025name in title: onasemnogene abeparvovec
PMID 40364205Post-Marketing Safety of Spinal Muscular Atrophy Therapies: Analysis of Spontaneous Adverse Drug Reactions from EudraVigilance.Journal of clinical medicine2025name in abstract: onasemnogene abeparvovec
PMID 40382143Gene replacement therapy to restore polyamine metabolism in a Snyder-Robinson syndrome mouse model.Methods in enzymology2025name in abstract: Zolgensma
PMID 40509660Costs of Treating Onasemnogene Abeparvovec-Xioi-Induced Liver Injury.Pharmacology research & perspectives2025name in title: onasemnogene abeparvovec
PMID 40538117Switching disease-modifying therapies in patients with spinal muscular atrophy: A systematic review on effectiveness outcomes.British journal of clinical pharmacology2025name in abstract: onasemnogene abeparvovec
PMID 40622452Early Intervention and Speed-to-Effect in Spinal Muscular Atrophy Type 1 Following Onasemnogene Abeparvovec Gene Replacement Therapy: Results of aPost-Hoc Analysis of Pooled Clinical Study Data.Neurology and therapy2025name in title: onasemnogene abeparvovec
PMID 40765022Pioneering SMA therapies for all types: survival gains, cost dynamics, and performance-based agreements.Cost effectiveness and resource allocation : C/E2025name in abstract: onasemnogene abeparvovec
PMID 40778350Safety and tolerability of onasemnogene abeparvovec for patients with spinal muscular atrophy weighing ≤17 kg and ≤24 months old from OFELIA, a phase 4, open-label, multicenter, non-randomised, interventional study.Lancet regional health. Americas2025name in title: onasemnogene abeparvovec
PMID 40803915Real-world experience with switch to onasemnogene abeparvovec after initial therapy with nusinersen or risdiplam.Neuromuscular disorders : NMD2025name in title: onasemnogene abeparvovec
PMID 40805927Pharmacoeconomic Profiles of Advanced Therapy Medicinal Products in Rare Diseases: A Systematic Review.Healthcare (Basel, Switzerland)2025name in abstract: onasemnogene abeparvovec
PMID 40868194Transforming Spinal Muscular Atrophy: From Pivotal Trials to Real-World Evidence and Future Therapeutic Frontiers in Types 1 and 2.Biomedicines2025name in abstract: onasemnogene abeparvovec
PMID 40868246Engineering Targeted Gene Delivery Systems for Primary Hereditary Skeletal Myopathies: Current Strategies and Future Perspectives.Biomedicines2025name in abstract: Zolgensma
PMID 40879810Combination therapies in spinal muscular atrophy: a systematic review.European journal of pediatrics2025name in abstract: onasemnogene abeparvovec
PMID 40986347Biomarkers of immune dysregulation and posttreatment inflammation in spinal muscular atrophy.Proceedings of the National Academy of Sciences of the United States of America2025name in abstract: Zolgensma
PMID 41001995SNAC: A Single-Nuclei Atlas of Capsid Distribution in Nonhuman Primate Eye.Human gene therapy2025name in abstract: Zolgensma
PMID 41007120Reduction in Perioperative Risk in Patients with Spinal Muscular Atrophy Following the Release of Disease-Modifying Therapies: An Analysis of the National Surgical Quality Improvement Program Database.Children (Basel, Switzerland)2025name in abstract: onasemnogene abeparvovec
PMID 41060652Comparative Clinical Outcomes of Nusinersen and Gene Therapy in Spinal Muscular Atrophy Type 1.JAMA network open2025name in abstract: onasemnogene abeparvovec
PMID 41133701Quebec Spinal Muscular Atrophy Newborn Screening Program: The First Year Experience.International journal of neonatal screening2025name in abstract: onasemnogene abeparvovec
PMID 41149786Diverging Safety Signals: A Trend Analysis of Suspected Adverse Drug Reactions Reporting for Spinal Muscular Atrophy Therapies in the European Union.Neurology international2025name in abstract: onasemnogene abeparvovec
PMID 41235102Gene Therapy in Rare Genetic Disorders: Current Progress and Future Perspectives.Current genomics2025name in abstract: Zolgensma
PMID 41283364Treating Presymptomatic Spinal Muscular Atrophy Patients with Onasemnogene Abeparvovec in Italy: The Role of the National Health System and Drug Supply. Comment on Zaidman et al. Newborn Screening for Spinal Muscular Atrophy: Variations in Practice and Early Management of Infants with Spinal Muscular Atrophy in the United States. Int. J. Neonatal Screen. 2024, 10, 58.International journal of neonatal screening2025name in title: onasemnogene abeparvovec
PMID 41283841[Onasemnogene abeparvovec gene replacement therapy for spinal muscular atrophy in children: a Moscow experience].Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova2025name in title: onasemnogene abeparvovec
PMID 41299848Pharmacokinetics of therapies approved for spinal muscular atrophy: A narrative review of current evidence.The Journal of international medical research2025name in abstract: onasemnogene abeparvovec
PMID 41303705Evaluation of the Telomere Length in Patients with Spinal Muscular Atrophy.International journal of molecular sciences2025name in abstract: onasemnogene abeparvovec
PMID 41350752Economic evaluations of disease-modifying therapies for spinal muscular atrophy: a systematic literature review.Orphanet journal of rare diseases2025name in abstract: onasemnogene abeparvovec
PMID 41362291Nonclinical toxicity study duration in AAV gene therapy development: Evidence from industry survey supports adequacy of short-term assessments.Molecular therapy. Methods & clinical development2025name in abstract: Zolgensma
PMID 41524367[Pharmacoeconomic evaluation of spinal muscular atrophy therapy in patients with four SMN2 copies diagnosed through newborn screening].Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova2025name in abstract: onasemnogene abeparvovec
PMID 41607656Circulating Tau Profiles in Pediatric and Adult Patients with Spinal Muscular Atrophy.medRxiv : the preprint server for health sciences2025name in abstract: onasemnogene abeparvovec
PMID 41607729Five-year disease-modifying therapeutic experience of 102 Chinese paediatric 5q-spinal muscular atrophy: a retrospective analysis.Brain communications2025name in abstract: Zolgensma

NIH grants

ProjectTitleOrganisationPIYearsLinked by
R01EB034573Engineering the biology of AAV secretion and productionDUKE UNIVERSITYASOKAN, ARAVIND2023–2026name in abstract: Zolgensma
R01NS076991Oligodendrocyte-focused rAAV gene therapy strategies for Canavan disease and LeukodystrophiesUNIV OF MASSACHUSETTS MED SCH WORCESTERGAO, GUANGPING2025–2026name in abstract: Zolgensma
R41NS143578Novel AAV gene therapy for treating CNS neuropathy of MPS IIICNEUROGT, INC.FU, HAIYAN2025–2026name in abstract: Zolgensma
R21AI180416Studies of the KIAA0319L-mediated productive transduction pathways of rAAV vectorsUNIVERSITY OF KANSAS MEDICAL CENTERQIU, JIANMING2024–2025name in abstract: Zolgensma
R21AI171265Mechanism of the Membrane-Associated Accessory Protein (MAAP) in rAAV ProductionUNIVERSITY OF KANSAS MEDICAL CENTERQIU, JIANMING2022–2023name in abstract: Zolgensma
R41TR004338Development of an Effective Strategy to Block Nab Activity for AAV Brain TransductionNABGEN, INC.ASKEW, CHARLES H2023–2023name in abstract: Zolgensma
R01FD007226Flexible Platform for End-to-end Manufacturing of Gene Therapies to Advance Development of Treatments for Ultra-rare DiseasesMASSACHUSETTS INSTITUTE OF TECHNOLOGYHAN, JONGYOON2020–2022name in abstract: Zolgensma
R15NS120154The neuropathology of cerebellum in spinal muscular atrophyDELAWARE STATE UNIVERSITYSUN, JIANLI2022–2022name in abstract: Zolgensma
R21AI166293Identification of the AAVR-independent AAV entry pathwayUNIVERSITY OF KANSAS MEDICAL CENTERQIU, JIANMING2021–2022name in abstract: Zolgensma
R41DK133021Rational design of AAV vectors with human hepatocyte tropism and neutralizing antibody evasionBEDROCK THERAPEUTICS, INC.LI, CHENGWEN2022–2022name in abstract: Zolgensma
R21NS118165Facilitate by-stander effects by EV-mRNA cargo in AAV gene therapy for MPS IIICUNIV OF NORTH CAROLINA CHAPEL HILLFU, HAIYAN2020–2020name in abstract: Zolgensma
R41AI155038Novel strategy to block AAV neutralizing anitbody activityNABGEN, INC.LI, CHENGWEN2020–2020name in abstract: Zolgensma
R41HL152923Develop humanized AAV vectors for liver targeting and neutralizing antibody evasionBEDROCK THERAPEUTICS, INC.LI, CHENGWEN2020–2020name in abstract: Zolgensma

Notes

AAV9 gene replacement for 5q spinal muscular atrophy. One program covering both formulations: the intravenous one (Zolgensma, onasemnogene abeparvovec-xioi, FDA 2019) and the intrathecal one (Itvisma, onasemnogene abeparvovec-brve, FDA 2025-11, for patients 2 years and older). SPEC section 1 says a new route or formulation of the same construct is not a new program, so they share this ID and have an approval row each; the FDA's four-letter suffixes differ but the INN does not. The EU authorisation was conditional in 2020 and became full on 2022-05-17.

How to cite

onasemnogene abeparvovec (AXP000250.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000250.html

Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.